Last reviewed · How we verify
LivaloVA
LivaloVA is a pitavastatin analog designed to lower cholesterol by inhibiting HMG-CoA reductase with enhanced potency and cardiovascular benefits.
LivaloVA is a pitavastatin analog designed to lower cholesterol by inhibiting HMG-CoA reductase with enhanced potency and cardiovascular benefits. Used for Hypercholesterolemia and dyslipidemia, Cardiovascular risk reduction.
At a glance
| Generic name | LivaloVA |
|---|---|
| Also known as | JW0101+C2101, Period III |
| Sponsor | JW Pharmaceutical |
| Drug class | HMG-CoA reductase inhibitor (statin) |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Pitavastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. LivaloVA represents a next-generation formulation or derivative intended to improve lipid-lowering efficacy and potentially reduce cardiovascular events in patients with dyslipidemia. The drug works by decreasing hepatic cholesterol production, leading to upregulation of LDL receptors and enhanced clearance of LDL cholesterol from the bloodstream.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Cardiovascular risk reduction
Common side effects
- Muscle pain or myalgia
- Elevated liver enzymes
- Headache
- Gastrointestinal disturbance
Key clinical trials
- To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension (PHASE3)
- To Evaluate the Pharmacokinetic Interactions and Safety in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LivaloVA CI brief — competitive landscape report
- LivaloVA updates RSS · CI watch RSS
- JW Pharmaceutical portfolio CI